A2 Vertaisarvioitu katsausartikkeli tieteellisessä lehdessä
Drug interactions with oral antidiabetic agents: pharmacokinetic mechanisms and clinical implications
Tekijät: Tornio A, Niemi M, Neuvonen PJ, Backman JT
Kustantaja: ELSEVIER SCIENCE LONDON
Julkaisuvuosi: 2012
Journal: Trends in Pharmacological Sciences
Tietokannassa oleva lehden nimi: TRENDS IN PHARMACOLOGICAL SCIENCES
Lehden akronyymi: TRENDS PHARMACOL SCI
Vuosikerta: 33
Numero: 6
Aloitussivu: 312
Lopetussivu: 322
Sivujen määrä: 11
ISSN: 0165-6147
DOI: https://doi.org/10.1016/j.tips.2012.03.001
Tiivistelmä
There is a growing epidemic of type 2 diabetes (T2DM), and it is associated with various comorbidities. Patients with T2DM are usually treated with multiple drugs, and are therefore at an increased risk of harmful drug drug interactions (DDIs). Several potentially life-threatening DDIs concerning oral antidiabetic drugs have been identified. This has mostly been initiated by case reports but, more recently, the understanding of their mechanisms has greatly increased. In this article, we review the pharmacokinetic DDIs concerning oral antidiabetics, including metformin, sulfonylureas, meglitinide analogs, thiazolidinediones and dipeptidyl peptidase-4 inhibitors, and the underlying mechanistic basis that can help to predict and prevent DDIs. In particular, the roles of membrane transporters and cytochrome P450 (CYP) enzymes in these DDIs are discussed.
There is a growing epidemic of type 2 diabetes (T2DM), and it is associated with various comorbidities. Patients with T2DM are usually treated with multiple drugs, and are therefore at an increased risk of harmful drug drug interactions (DDIs). Several potentially life-threatening DDIs concerning oral antidiabetic drugs have been identified. This has mostly been initiated by case reports but, more recently, the understanding of their mechanisms has greatly increased. In this article, we review the pharmacokinetic DDIs concerning oral antidiabetics, including metformin, sulfonylureas, meglitinide analogs, thiazolidinediones and dipeptidyl peptidase-4 inhibitors, and the underlying mechanistic basis that can help to predict and prevent DDIs. In particular, the roles of membrane transporters and cytochrome P450 (CYP) enzymes in these DDIs are discussed.
Turun yliopiston Tutkimustietojärjestelmän portaali